Urotronic Inc.   Report issue

For profit Phase 2
Founded: Minneapolis MN United States (2015)
Status: Acquired by Laborie Medical Technologies (2023)

Organization Overview

First Clinical Trial
2017
NCT03423979
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Urotronic Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

paclitaxel (taxol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hyperplasia (Phase 2)

Hypertrophy (Phase 2)

Prostatic Hyperplasia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1